Aditum Bio co-founders Joe Jimenez (L) and Mark Fishman
Exclusive: Joe Jimenez's Aditum Bio rings in new year with $428M third fund
The first biopharma venture fund to close in 2025 comes from industry veterans Joe Jimenez and Mark Fishman, two former Novartis leaders.
Jimenez exclusively told …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
